Skip to main content

Table 1 Clinical and histopathological characteristics of ILC and IDC patients

From: Associations between the standardized uptake value of 18F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma

  Total ( n = 105) ILC ( n = 32) IDC ( n = 73) P value
Age (n = 105; 32, 73)a 52 ± 9.46 53.28 ± 9.52 51.44 ± 9.44 0.529
Tumor size (n = 104; 31, 73)a 2.25 ± 1.56 2.64 ± 1.13 2.08 ± 1.69 0.002
Tumor Grade (n = 105; 32, 73)a     0.709
 Grade 1 35 (33.3) 9 (28.1) 26 (35.6)  
 Grade 2 53 (50.5) 18 (56.3) 35 (48.0)  
 Grade 3 17 (16.2) 5 (15.6) 12 (16.4)  
ER (n = 104; 31, 73)a     0.031
 Negative 20 (19.2) 2 (6.5) 18 (24.7)  
 Positive 84 (80.8) 29 (93.6) 55 (75.3)  
PR (n = 103; 31, 72)a     0.023
 Negative 33 (32.0) 5 (16.1) 28 (38.9)  
 Positive 70 (68.0) 26 (83.9) 44 (61.1)  
HER2 (n = 91; 30, 61)a     0.039
 Negative 74 (81.3) 28 (93.3) 46 (75.4)  
 Positive 17 (18.7) 2 (6.7) 15 (24.6)  
EGRF (n = 98; 27, 71)a     0.221
 Negative 82 (83.7) 25 (92.6) 57 (80.3)  
 Positive 16 (16.3) 2 (7.4) 14 (19.7)  
Ki-67 (n = 99; 27, 72)a     0.003
 Negative 57 (57.6) 22 (81.5) 35 (48.6)  
 Positive 42 (42.4) 5 (18.5) 37 (51.4)  
  1. Note: The age and tumor size were shown in mean ± standard deviation (SD) and other values were presented as number of cases and percentage in parenthesis.
  2. a(n = number of total cases; number of ILC, number of IDC).
  3. EGRF, epidermal growth factor receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor.